The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme.

Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease manifests as muscle weakness and can become life-threatening in severe ...

UCB will contribute three presentations, including data on the disease course of thymidine kinase 2 deficiency (TK2d) in untreated patients and insights into caregiver impact These data emphasize ...

A UCB drug with a novel approach to plaque psoriasis won a long-awaited FDA approval, positioning it to bring patients a new choice in a crowded market of products for the prevalent skin condition.

UCB plans to acquire Ra Pharmaceuticals for approximately $2.1 billion, the companies said today, in a deal designed to expand the buyer’s presence in rare disease therapeutics by adding to its ...

UCB’s $2.5 billion gamble on Ra Pharmaceuticals has yielded positive phase 3 data. With the rare disease clinical trial hitting its primary endpoint, UCB is preparing to file to join AstraZeneca and ...

Regional banking company United Community Banks (NYSE:UCB) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 6.1% year on year to $260.2 million. Its non-GAAP profit of $0.66 per ...

A Belgian drugmaker is spending more than $2 billion to acquire a company developing a drug to treat several rare and serious diseases. Brussels-based UCB said on Thursday that it would acquire ...

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with UCB, which struck a $2.5 billion (€2.2 billion) deal to acquire Ra Pharmaceuticals. The deal will move UCB onto ...

BRUSSELS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement ...

Another Massachusetts biotech is being bought by a big foreign drug company. Belgian-based UCB said Thursday it plans to buy Ra Pharmaceuticals, a Cambridge, Mass., company that is developing ...